Ashton Thomas Securities’s Novo Nordisk NVO Stock Holding History

Ashton Thomas Securities’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$563K	Buy	11,734 +932	+9%	+$40K	0.08%	201
2026 Q1	$397K	Buy	10,802 +116	+1%	+$5.5K	0.05%	270
2025 Q4	$545K	Buy	10,686 +453	+4%	+$23.2K	0.1%	172
2025 Q3	$568K	Buy	10,233 +1,766	+21%	+$103K	0.08%	212
2025 Q2	$584K	Buy	8,467 +70	+0.8%	+$4.76K	0.14%	154
2025 Q1	$583K	Buy	8,397 +2,598	+45%	+$215K	0.16%	143
2024 Q4	$499K	Sell	5,799 -5,225	-47%	-$565K	0.14%	147
2024 Q3	$1.31M	Buy	11,024 +1,899	+21%	+$253K	0.26%	92
2024 Q2	$1.28M	Buy	+9,125	New	+$1.21M	0.31%	83

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Ashton Thomas Securities's NVO Position: Q2 2026 in Review

Ashton Thomas Securities increased its Novo Nordisk (NVO) stake by 8.6% in Q2 2026, buying an estimated $40K and bringing the position to 11,734 shares worth $563K. The position accounts for 0.08% of the portfolio, ranked #201.

Ashton Thomas Securities first reported a position in NVO in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.31M in Q3 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Ashton Thomas Securities held 11,734 shares of Novo Nordisk worth $563K as of Q2 2026.
Ashton Thomas Securities bought 932 Novo Nordisk shares in Q2 2026, an estimated $40K.
Novo Nordisk made up 0.08% of Ashton Thomas Securities's portfolio in Q2 2026, its #201 holding.
Ashton Thomas Securities first reported a position in Novo Nordisk in Q2 2024 and has held it in 9 quarters since.
Ashton Thomas Securities's Novo Nordisk position peaked at $1.31M in Q3 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Ashton Thomas Securities's 13F filing for Q2 2026, filed 27 Jul 2026.